blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3735589

EP3735589 - ANTIBODY-MEDIATED NEUTRALIZATION OF CHIKUNGUNYA VIRUS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  15.12.2023
Database last updated on 26.06.2024
FormerRequest for examination was made
Status updated on  09.10.2020
FormerThe international publication has been made
Status updated on  17.08.2019
Formerunknown
Status updated on  10.06.2019
Most recent event   Tooltip18.05.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Vanderbilt University
305 Kirkland Hall
2201 West End Avenue
Nashville, TN 37240 / US
[2020/46]
Inventor(s)01 / CROWE, James, E., Jr.
C/o Vanderbilt University Medical Center 11475
MRB IV, 2213 Garland Ave.
Nashville, TN 37232 / US
 [2020/46]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2020/46]Potter Clarkson
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date19727754.404.01.2019
[2020/46]
WO2019US12313
Priority number, dateUS201862614010P05.01.2018         Original published format: US 201862614010 P
[2020/46]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2019156758
Date:15.08.2019
Language:EN
[2019/33]
Type: A2 Application without search report 
No.:EP3735589
Date:11.11.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 15.08.2019 takes the place of the publication of the European patent application.
[2020/46]
Search report(s)International search report - published on:EP10.10.2019
(Supplementary) European search report - dispatched on:EP14.12.2023
ClassificationIPC:G01N33/569, A61K39/395, C07K16/10
[2020/46]
CPC:
G01N33/56983 (EP,US); C07K16/1081 (EP,US); A61K39/42 (US);
A61P31/14 (US); A61K2039/505 (EP,US); C07K2317/21 (EP);
C07K2317/24 (US); C07K2317/56 (US); C07K2317/565 (US);
C07K2317/76 (EP,US); C07K2317/92 (EP); Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/46]
TitleGerman:ANTIKÖRPERVERMITTELTE NEUTRALISIERUNG DES CHIKUNGUNYA-VIRUS[2020/46]
English:ANTIBODY-MEDIATED NEUTRALIZATION OF CHIKUNGUNYA VIRUS[2020/46]
French:NEUTRALISATION À MÉDIATION PAR ANTICORPS DU VIRUS CHIKUNGUNYA[2020/46]
Entry into regional phase03.08.2020National basic fee paid 
03.08.2020Designation fee(s) paid 
03.08.2020Examination fee paid 
Examination procedure03.08.2020Examination requested  [2020/46]
03.08.2020Date on which the examining division has become responsible
16.02.2021Amendment by applicant (claims and/or description)
14.12.2023Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M06) [2024/03]
14.12.2023Despatch of a communication from the examining division (Time limit: M06)
16.05.2024Reply to a communication from the examining division
Fees paidRenewal fee
03.08.2020Renewal fee patent year 03
27.01.2022Renewal fee patent year 04
27.01.2023Renewal fee patent year 05
29.01.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2016168417  (UNIV VANDERBILT [US]) [I] 1-67* the whole document *
by applicantUS3817837
 US3850752
 US3939350
 US3996345
 US4196265
 US4275149
 US4277437
 US4366241
 US4472509
 US4554101
 US4680338
 US4816567
 US4867973
 US4938948
 US5021236
 US5141648
 US5196066
 US5563250
 US5565332
 US5856456
 US5880270
    - Goding, (19860000), pages 71 - 74
    - Campbell, (19840000), pages 75 - 83
    - "Uniprot", Database accession no. #Q8JUX5
    - ABBONDANZO et al., Am. J. Pediatr. Hematol. Oncol., (19900000), vol. 12, no. 4, pages 480 - 489
    - ALLRED et al., Arch. Surg., (19900000), vol. 125, no. 1, pages 107 - 113
    - ATHERTON et al., Biol. of Reproduction, (19850000), vol. 32, pages 155 - 171
    - AUSTIN et al., PLoS Pathog, (20120000), vol. 8, page el002930
    - BREHIN et al., Virology, (20080000), vol. 371, pages 185 - 195
    - BROWN et al., J. Immunol. Meth., (19900000), vol. 130, no. 1, pages 111 - 121
    - CAMPBELL, Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier, (19840000), vol. 13, pages 75 - 83
    - Biochem. Biophys. Res. Comm., (19770000), vol. 74, no. 2, pages 425 - 433
    - CHRISTIAN et al., Proc Natl Acad Sci USA, (20130000), vol. 110, pages 18662 - 18667
    - CHU et al., "Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model", Vaccine, (20130000), vol. 31, doi:doi:10.1016/j.vaccine.2013.05.059, pages 3353 - 3360, XP028595583

DOI:   http://dx.doi.org/10.1016/j.vaccine.2013.05.059
    - COUDERC et al., J. Infect. Dis., (20090000), vol. 200, pages 516 - 523
    - DE JAGER et al., Semin. Nucl. Med., (19930000), vol. 23, no. 2, pages 165 - 179
    - DHOLAKIA et al., J. Biol. Chem., (19890000), vol. 269, pages 10210 - 10218
    - DOOLITTLEBEN-ZEEV, Methods Mol. Biol., (19990000), vol. 109, pages 215 - 237
    - EDWARDS et al., J. Gen. Virol., (19860000), vol. 67, no. 2, pages 377 - 380
    - HALLENGARD et al., J. Virol., (20140000), vol. 88, pages 12233 - 12241
    - FRIC et al., J. Infect. Dis., (20130000), vol. 207, pages 319 - 322
    - GEFTER et al., Somatic Cell Genet., (19770000), vol. 3, pages 231 - 236
    - GOH et al., Clin. Immunol., (20130000), vol. 149, pages 487 - 497
    - GULBISGALAND, Hum. Pathol., (19930000), vol. 24, no. 12, pages 1271 - 1285
    - GUO et al., ci. Transl. Med., (20010000), vol. 3, page 99 ra85
    - HONG et al., J. Virol., (20130000), vol. 87, pages 12471 - 12480
    - KAM et al., EMBO Mol. Med., (20120000), vol. 4, pages 330 - 343
    - KRAUSE et al., J. Virol., (20120000), vol. 86, pages 13005 - 13015
    - KAM et al., PLoS One, (20140000), vol. 9, page e95647
    - KHATOON et al., Ann. of Neurology, (19890000), vol. 26, pages 210 - 219
    - KIELIAN et al., Viruses, (20100000), vol. 2, pages 796 - 825
    - KOHLERMILSTEIN, Eur. J. Immunol., (19760000), vol. 6, pages 511 - 519
    - KOHLERMILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497
    - WARTER et al., J. Immunol., (20110000), vol. 186, pages 3258 - 3264
    - KRAUSE et al., J. Virol., (20100000), vol. 84, pages 3127 - 3130
    - KRAUSE et al., J. Virol., (20110000), vol. 85, pages 10905 - 10908
    - KYTEDOOLITTLE, J. Mol. Biol., (19820000), vol. 157, no. 1, pages 105 - 132
    - LANCIOTTIVALADERE, Emerg Infect Dis, (20140000), vol. 20
    - LEE et al., PLoS Pathog, (20110000), vol. 7, page el002390
    - LEVITT et al., Vaccine, (19860000), vol. 4, pages 157 - 162
    - LUM et al., J. Immunol., (20130000), vol. 190, pages 6295 - 6302
    - SMITH et al., MBio, (20130000), vol. 4, pages e00873 - 00813
    - MASRINOUL et al., Virology, (20140000), vol. 464-465, pages 111 - 117
    - MESSER et al., Proc. Natl. Acad. Sci. U. S. A., (20140000), vol. 111, pages 1939 - 1944
    - MORRISON et al., Am J Pathol, (20110000), vol. 178, pages 32 - 40
    - O'SHANNESSY et al., J. Immun. Meth., (19870000), vol. 99, pages 153 - 161
    - PAES et al., J. Am. Chem. Soc., (20090000), vol. 131, pages 6952 - 6954
    - PAL et al., PLoS Pathog, (20130000), vol. 9, page el003312
    - PERSIC et al., Gene, (19970000), vol. 187, page 1
    - POTTERHALEY, Meth. Enzymol., (19830000), vol. 91, pages 613 - 633
    - Remington's Pharmaceutical Sciences, (19900000), vol. 3, pages 624 - 652
    - SELVARAJAH et al., PLoS Negl. Trop. Dis., (20130000), vol. 7, page e2423
    - SISSOKO et al., PLoS Negl. Trop. Dis., (20090000), vol. 3, page e389
    - SMITH et al., J. Infect. Dis, (20130000), vol. 207, pages 1898 - 1908
    - STAPLES et al., Clin. Infect. Dis., (20090000), vol. 49, pages 942 - 948
    - SUN et al., Elife, (20130000), vol. 2, page e00435
    - SUN et al., J. Steroid Biochem., (19870000), vol. 26, no. 1, pages 83 - 92
    - TANG et al., J. Biol. Chem., (19960000), vol. 271, pages 28324 - 28330
    - THORNBURG et al., J. Clin. Invest., (20130000), vol. 123, pages 4405 - 4409
    - VANDER VEEN et al., Anim Health Res Rev, (20120000), vol. 13, pages 1 - 9
    - VOSS et al., Nature, (20100000), vol. 468, pages 709 - 712
    - WAWRZYNCZAKTHORPE, Immunoconjugates, Antibody Conuugates In Radioimaging And Therapy Of Cancer, Oxford University Press, (19870000), vol. 28
    - YU et al., Nature, (20080000), vol. 455, pages 532 - 536
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.